Merck Discontinues Two More Phase III Keytruda Studies

 
• By Joseph Haas
  
Pembrolizumab
Merck said it is giving up on two Phase III label-expansion studies for Keytruda • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer